Longeveron closed a private placement for up to USD 30 million in gross proceeds, priced at-the-market under Nasdaq rules. The initial closing raised about USD 15 million in gross proceeds, led by Coastlands Capital with participation from Janus Henderson Investors. Longeveron issued 6.01 million Class A shares at USD 0.52 per share and Series A non-voting convertible preferred stock convertible into 22.83 million Class A shares. The company may receive up to an additional USD 15 million in gross proceeds subject to milestone-driven conditions tied to its Phase 2b ELPIS II trial in HLHS and share price. Longeveron also agreed to sell investors an interest in 50% of proceeds from any future sale of a Rare Pediatric Disease Priority Review Voucher related to its HLHS program.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief on March 11, 2026, and is solely responsible for the information contained therein.
Comments